HSRN DATA BRIEF: NATIONAL SALES PERSPECTIVES TM
`
`
`
`DATA SUMMARY
`The National Sales PerspectivesTM (NSP) is considered the industry standard for measuring
`pharmaceutical spending. This is because NSP captures 100% of the total U.S. pharmaceutical
`market, measuring sales at actual transaction prices rather than using an average wholesale price.
`The NSP is used by a variety of healthcare policy setters and decision makers to monitor and
`assess national sales given its accuracy representing 100% of the U.S. pharmaceutical sales
`market.
`
`DATA SAMPLE
`The IMS National Sales Perspectives monitors every major class of trade and channel of
`distribution for prescription pharmaceuticals, over-the-counter products and select, self-
`administered diagnostic products in the United States, measuring volume of dollars and units
`moving from manufacturers into various outlets within all 50 states.
`
`Universe
`The IMS sales database is derived from the processing of more than 1.5 billion transactions each
`year. These transactions reflect both direct sales from approximately 100 pharmaceutical
`companies and indirect sales information from over 700 distribution centers. The universe of
`these direct and indirect sales are made to over 552 wholesalers, 223 drug and food chain
`warehouses, 5,793 non-federal hospitals and 334 federal government and non-government mail
`service pharmacies.
`
`Sample
`The NSP data is derived from a sample of the universe based on information provided by reporting
`manufacturers and projected to 100% of the total market. In addition, the NSP sample includes
`indirect sales of retail & non-retail channels currently collected from 322 wholesalers and 60 drug
`chain distributors, a panel of over 300 non-federal hospitals, and 142 mail service pharmacies.
`This data is obtained from invoice data sent to IMS by various suppliers via electronic submission.
`
`ALTERNATIVE SOURCES OF SIMILAR DATA
`, which is described in another HSRN
`The NSP is distinct from the IMS National Prescription Audit
`Data Brief. Whereas the National Prescription Audit captures the demand for prescription drugs
`across retail, standard mail service, specialty mail service, and long-term care, the NSP focuses on
`the sales and distribution of prescription, over-the-counter, and select self-administered diagnostic
`products from manufacturers into various outlets. There are two alternate data sources of sales
`information - NDC PHAST by Wolters Kluwer and SDI’s VONA. Both NDC PHAST and Vona
`estimate retail prescription prices. NSP is the only industry source of true sales into both retail
`and non-retail pharmacies. NSP’s use of invoice price to the pharmacy is the best representation
`of actual product or market potential and is a critical input towards measuring true sales. For
`example, the utilization of actual transaction prices enables the most accurate projections for
`genericized markets which are highly price sensitive. Other key NSP advantages include exclusive
`supplier agreements with Caremark Therapeutic Services (CTS) and Omnicare. CTS provides
`unique insights into specialty pharmaceutical mail service and Omnicare provides key insights into
`the Long Term Care channel as the nation’s largest nursing home provider.
`
`200 Campus Drive, Collegeville, PA 19426
`
`AstraZeneca Exhibit 2137
`Mylan v. AstraZeneca
`IPR2015-01340
`
`Page 1 of 2
`
`

`
`
`
`
`
`
`
`
`
`
`
`
`
`
`KEY DATA ELEMENTS
`NSP provides data elements related to the sales dollars and volume of pharmaceutical products to
`retail and non-retail outlets. Sales Dollars or extended units are the recommended measure for
`capturing sales volume.
`Category
`Data Details
`Product
` Anatomical classification/ USC
`drug classification code
` Form/strength
` Manufacturer/corporation/launch
`date
` Sales Dollars
` Eaches (Injectable Vials)
` Units (Bottles or packaged unit)
` Kilograms
`Retail
` Chain Stores
` Food Stores
` Mass Merchandisers
`Independents
`
` Mail Service (Unprojected)
`
`
`Sales
`
`Class of Trade
`
`
`
`
`
` Extended Units (numbers of pills
`or milliliters of liquid)
`
`
`Non-Retail
` Non-Federal Hospitals
` Federal Facilities
` HMOs
` Clinics
` Long-Term Care
` Home Healthcare
` Misc. (Prisons, Universities, etc.)
`
`
`PUBLICATIONS USING DATA SOURCE
`The National Sales Perspectives database is particularly valuable for addressing research questions
`that focus on trends or estimates of supply-side sales volume or costs. Below are examples of
`recently published works using the NSP.
`
`1.Hicks LA, Suda KJ, Roberts RM, Hunkler RJ, Taylor TH, Danziger LH. Data Reveal Wide Geographic
`Variability in Antimicrobial Use in the United States, 2009. Poster, Infectious Disease Society of
`America,October, 2010. http://idsa.confex.com/idsa/2010/webprogram/Paper3571.htmland Poster,
`Infectious Disease Society of America, October, 2010
`The authors used National Sales Perspective™ (NSP) to document that roughly two-thirds of U.S. sales of
`antibiotics in 2009 were distributed through non-acute channels. Additional observations were made
`through the use of Xponent™: A group of Southern states exhibited inordinately high prescribing rates of
`all classes of antibiotics; and states in which CDC-funded appropriate antibiotic use campaigns were in
`place exhibited below-average prescribing rates.
`
`2.Philipson T, Berndt ER, Gottschalk AHB, Sun E. Cost-Benefit Analysis of the FDA: The Case of the
`Prescription Drug User Fee Acts. Journal of Public Economics. 2008;92:1306-1325.
`http://web.mit.edu/cbi/publications/JPubE_Philipson.pdf
`The authors used National Sales Perspectives™ (NSP) data to estimate the welfare effects of the
`Prescription Drug User Fee Acts (PDUFA). They found that PDUFA raised the private surplus of producers by
`about $7 to $11 billion and raised consumer welfare between $7 to $20 billion; thus the combined social
`surplus was raised by $14 to $31 billion, which is the equivalent of 140,000 to 310,000 life years.
`
`3.Alexander GC, Sehgal NL, Moloney RM, Stafford RS. National Trends in Treatment of Type 2 Diabetes
`Mellitus, 1994-2007. Archives of Internal Medicine. 2008;168:2088-2094.
`http://www.ncbi.nlm.nih.gov/pubmed/18955637
`The authors used the National Disease and Therapeutic Index™ (NDTI), National Prescription Audit™(NPA),
`and National Sales Perspective™ (NSP) to analyze medications prescribed between 1994-2007 for Type 2
`diabetes. They also estimate total costs of diabetes treatments between 2001 and 2008. They conclude
`that increasingly complex and costly diabetes treatments are being applied to a growing population.
`
`Page 2 of 2